Long-term treatment with ganaxolone for seizures associated with CDKL5 Deficiency Disorder: 2-year open-label extension follow-up

被引：0
|
作者：
Miller, I
Demarest, S.
Bahi-Buisson, N.
Pestana-Knight, E.
Devinsky, O.
Amin, S.
Marsh, E.
Aimetti, A.
Hulihan, J.
Olson, H.
机构：
来源：
ANNALS OF NEUROLOGY | 2023年 / 94卷
关键词：
Epilepsy; Neurodevelopmental Disorders;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
84
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] Long-term treatment with ganaxolone for seizures associated with CDKL5 deficiency disorder: 2-year open-label extension follow-up
    Bahi-Buisson, N.
    Olson, H.
    Pestana-Knight, E.
    Devinsky, O.
    Amin, S.
    Marsh, E.
    Aimetti, A.
    Miller, I.
    Hulihan, J.
    Demarest, S.
    EPILEPSIA, 2023, 64 : 158 - 158
  • [2] Extended duration ganaxolone treatment for seizures associated with CDKL5 Deficiency Disorder: 1-year minimum open-label extension follow-up
    Pestana-Knight, E.
    Demarest, S.
    Devinsky, O.
    Amin, S.
    Aimetti, A.
    Rybak, E.
    Miller, I
    Hulihan, J.
    Olson, H.
    ANNALS OF NEUROLOGY, 2022, 92 : S72 - S73
  • [3] Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up
    Olson, Heather E.
    Amin, Sam
    Bahi-Buisson, Nadia
    Devinsky, Orrin
    Marsh, Eric D.
    Pestana-Knight, Elia
    Rajaraman, Rajsekar R.
    Aimetti, Alex A.
    Rybak, Eva
    Kong, Fanhui
    Miller, Ian
    Hulihan, Joseph
    Demarest, Scott
    EPILEPSIA, 2024, 65 (01) : 37 - 45
  • [4] Ganaxolone for management of seizures associated with CDKL5 deficiency disorder
    Yasmen, Nelufar
    Sluter, Madison N.
    Yu, Ying
    Jiang, Jianxiong
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (02) : 128 - 129
  • [5] Extended duration safety and efficacy of adjunctive ganaxolone treatment in patients with CDKL5 deficiency disorder: 8-month minimum open-label extension follow-up
    Olson, H.
    Moosa, A.
    Rybak, E.
    Aimetti, A.
    Hulihan, J.
    Pestana-Knight, E.
    EPILEPSIA, 2022, 63 : 235 - 236
  • [6] Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study
    Haab, Francois
    Corcos, Jacques
    Siami, Paul
    Glavind, Karin
    Dwyer, Peter
    Steel, Michael
    Kawakami, Fernando
    Lheritier, Karine
    Steers, William D.
    BJU INTERNATIONAL, 2006, 98 (05) : 1025 - 1032
  • [7] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
    Wroe, S.
    Duncan, R.
    EPILEPSIA, 2006, 47 : 138 - 138
  • [8] Cisapride in the long-term treatment of chronic gastroparesis: A 2-year open-label study
    Kendall, BJ
    Kendall, ET
    Soykan, I
    McCallum, RW
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1997, 25 (04) : 182 - 189
  • [9] Ganaxolone, an Investigational Neurosteroid Treatment for Children with CDKL5 Deficiency Disorder: Results from a Phase 2 Trial
    Rogawski, Michael
    Masuoka, Lorianne
    Specchio, Nicola
    Chez, Michael
    Tarquinio, Daniel
    Lappalainen, Jaakko
    Tsai, Julia
    NEUROTHERAPEUTICS, 2018, 15 (03) : 826 - 827
  • [10] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
12345